

Jörg Cammenga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/274426/publications.pdf>

Version: 2024-02-01

30
papers

800
citations

687363

13
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

1627
citing authors

#	ARTICLE	IF	CITATIONS
1	Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. <i>Blood</i> , 2017, 129, 2266-2279.	1.4	152
2	Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR. <i>Cell</i> , 2019, 177, 1201-1216.e19.	28.9	100
3	SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. <i>Leukemia</i> , 2018, 32, 1106-1115.	7.2	89
4	Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis. <i>Stem Cell Reports</i> , 2016, 7, 11-18.	4.8	53
5	Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. <i>HemaSphere</i> , 2019, 3, e321.	2.7	51
6	Hematopoietic Stem Cells Are Intrinsically Protected against MLL-ENL-Mediated Transformation. <i>Cell Reports</i> , 2014, 9, 1246-1255.	6.4	47
7	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. <i>Blood Advances</i> , 2020, 4, 1094-1101.	5.2	44
8	RUNX1 cooperates with FLT3-ITD to induce leukemia. <i>Journal of Experimental Medicine</i> , 2017, 214, 737-752.	8.5	38
9	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. <i>Blood</i> , 2018, 132, 2309-2313.	1.4	38
10	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. <i>Blood</i> , 2019, 134, 1558-1561.	1.4	38
11	Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NF- κ B-dependent differentiation of AML cells. <i>Blood Advances</i> , 2017, 1, 2046-2057.	5.2	35
12	Ataxia-pancytopenia syndrome with SAMD9L mutations. <i>Neurology: Genetics</i> , 2017, 3, e183.	1.9	24
13	Acute myeloid leukemia in very old patients. <i>Haematologica</i> , 2018, 103, e578-e580.	3.5	17
14	A risk score based on real-world data to predict early death in acute promyelocytic leukemia. <i>Haematologica</i> , 2022, 107, 1528-1537.	3.5	12
15	Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation. <i>Leukemia Research Reports</i> , 2015, 4, 72-75.	0.4	10
16	Hif-1 Δ Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML. <i>Stem Cell Reports</i> , 2019, 12, 112-121.	4.8	10
17	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	2.2	7
18	Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 426-433.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Hypoxic induction of vascular endothelial growth factor regulates erythropoiesis but not hematopoietic stem cell function in the fetal liver. <i>Experimental Hematology</i> , 2014, 42, 941-944.e1.	0.4	6
20	Small molecule screen identifies differentiation-promoting compounds targeting genetically diverse acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 342-346.	2.5	5
21	Familial platelet disorder due to germline exonic deletions in <i>RUNX1</i> : a diagnostic challenge with distinct alterations of the transcript isoform equilibrium. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	5
22	Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. <i>Experimental Hematology and Oncology</i> , 2021, 10, 7.	5.0	4
23	Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1973-1981.	1.3	4
24	A somatic mutation in moesin drives progression into acute myeloid leukemia. <i>Science Advances</i> , 2022, 8, eabm9987.	10.3	2
25	A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRC embryonic stem cell lines. <i>Genesis</i> , 2018, 56, e23238.	1.6	1
26	Cytopenia, Predisposition to Myelodysplastic Syndrome, Immunodeficiency, and Neurological Disease Caused By Gain-of-Function SAMD9L Mutations Is Frequently Ameliorated By Hematopoietic Revertant Mosaicism. <i>Blood</i> , 2016, 128, 4299-4299.	1.4	1
27	Smad4 as a Therapeutic Target in Nup98-HoxA9-Induced Leukemia.. <i>Blood</i> , 2008, 112, 1799-1799.	1.4	0
28	Hypoxic Induction of Vascular Endothelial Growth Factor Regulates Fetal Erythropoiesis but Not Stem Cell Function. <i>Blood</i> , 2011, 118, 4823-4823.	1.4	0
29	Up-Regulation of Flt3 Is a Passive Event in Hoxa9/Meis1-Induced Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2441-2441.	1.4	0
30	Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 4351-4351.	1.4	0